Lingfeng has been working for Pfizer for more than four years (including for legacy Wyeth) as a clinical statistician for drug development in the Primary Care Business Unit, collaborating with different clinical teams for Pristiq, Bapineuzumab, ACC, and Viviant programs. His responsibilities include study design, protocol development, data analysis, and interactions with U.S. and global regulatory agencies.
GBCHealth is partnering with the GHF program in 2012-2013 to design and implement a new initiative to engage businesses in diabetes prevention and care efforts across China. By sharing chronic disease experience with GBCHealth, Global Health Fellows will play a critical role in building this critical advocacy and prevention initiative and expanding the business community's contributions to address this growing public health concern.
From his GHF experience, Lingfeng hopes to gain first-hand experience in disease management and prevention in China, especially for non-communicable chronic diseases, which may present a tremendous marketing opportunity for future drug development. Lingfeng also believes that his leadership, communication, and management skills, strengthened by exposure to a diverse cultural environment, will greatly enhance his contribution to Pfizer in an industry that increasingly requires holistic and global approaches for sustainable success.
GBCHealth is a coalition of more than 220 companies united to keep the fight against HIV/AIDS, tuberculosis, malaria, and non-communicable diseases a global priority. The Coalition's members share learning and knowledge from the front lines of the fight, and GBC provides tailored support so that companies can take an active role in defeating the pandemics. GBC also organizes collective actions among companies, and links the public and private sectors in ways that pool talents and resources. GBC represents the private sector to the Global Fund.